CAT

928.77

-0.7%↓

322.53

+2.04%↑

GEV.US

944.76

-4.21%↓

RTX

179.06

+1.73%↑

215.4

+0.35%↑

CAT

928.77

-0.7%↓

322.53

+2.04%↑

GEV.US

944.76

-4.21%↓

RTX

179.06

+1.73%↑

215.4

+0.35%↑

CAT

928.77

-0.7%↓

322.53

+2.04%↑

GEV.US

944.76

-4.21%↓

RTX

179.06

+1.73%↑

215.4

+0.35%↑

CAT

928.77

-0.7%↓

322.53

+2.04%↑

GEV.US

944.76

-4.21%↓

RTX

179.06

+1.73%↑

215.4

+0.35%↑

CAT

928.77

-0.7%↓

322.53

+2.04%↑

GEV.US

944.76

-4.21%↓

RTX

179.06

+1.73%↑

215.4

+0.35%↑

Home・Listă Acțiuni・Ocugen Inc

Ocugen Inc

Deschisă

1.34 2.29

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

1.3

Maxim

1.35

Indicatori cheie
By Trading Economics
Venit	-1.5M -19M
Vânzări	1.7M 1.5M
EPS	-0.06
Marjă de profit	-1,250.946
Angajați	116
EBITDA	-987K -17M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+752.99% upside

Dividende
By Dow Jones
Următoarele câștiguri	31 iul. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-162M 464M
Deschiderea anterioară	-0.95
Închiderea anterioară	1.34

Ocugen Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 iun. 2026, 23:22 UTC

Câștiguri

Principalele dinamici ale pieței

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3 iun. 2026, 23:09 UTC

Acțiuni populare

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3 iun. 2026, 20:51 UTC

Câștiguri

Costco Reports 15% Sales Growth in May

3 iun. 2026, 20:43 UTC

Câștiguri

Broadcom 2Q Revenue Climbs on AI Chip Demand

3 iun. 2026, 23:48 UTC

Market Talk

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3 iun. 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 iun. 2026, 23:35 UTC

Market Talk

Oil Futures Fall on Possible Technical Correction -- Market Talk

3 iun. 2026, 23:15 UTC

Market Talk

Câștiguri

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3 iun. 2026, 22:08 UTC

Acțiuni populare

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3 iun. 2026, 21:54 UTC

Market Talk

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3 iun. 2026, 21:18 UTC

Câștiguri

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3 iun. 2026, 21:15 UTC

Câștiguri

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3 iun. 2026, 21:13 UTC

Câștiguri

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3 iun. 2026, 21:13 UTC

Câștiguri

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3 iun. 2026, 21:12 UTC

Câștiguri

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3 iun. 2026, 21:09 UTC

Câștiguri

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3 iun. 2026, 21:03 UTC

Câștiguri

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3 iun. 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 iun. 2026, 20:43 UTC

Câștiguri

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3 iun. 2026, 20:39 UTC

Achiziții, Fuziuni, Preluări

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3 iun. 2026, 20:37 UTC

Achiziții, Fuziuni, Preluări

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3 iun. 2026, 20:35 UTC

Câștiguri

Broadcom Stock Falls Despite Record Results -- Barrons.com

3 iun. 2026, 20:21 UTC

Achiziții, Fuziuni, Preluări

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3 iun. 2026, 20:17 UTC

Câștiguri

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3 iun. 2026, 20:17 UTC

Câștiguri

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3 iun. 2026, 20:15 UTC

Achiziții, Fuziuni, Preluări

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3 iun. 2026, 20:15 UTC

Câștiguri

Broadcom 2Q Adj EPS $2.44 >AVGO

3 iun. 2026, 20:15 UTC

Câștiguri

Broadcom 2Q EPS $1.91 >AVGO

3 iun. 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3 iun. 2026, 20:15 UTC

Câștiguri

Broadcom 2Q Rev $22.19B >AVGO

Comparație

Modificare preț

Ocugen Inc Așteptări

Obiectiv de preț

By TipRanks

752.99% sus

Prognoză pe 12 luni

Medie 11.43 USD 752.99%

Maxim 22 USD

Minim 7 USD

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruOcugen Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

7 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 7 analiști care au acordat evaluări ale acțiunilor Ocugen Inc - Dist în ultimele 3 luni.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.